{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-012807","form_type":"8-K","ticker":"LUCD","cik":"0001799011","company_name":"Lucid Diagnostics Inc.","filed_at":"2026-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.212393+00:00","generated_at":"2026-05-15T08:52:09.138095+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lucid Diagnostics Q4 2025 revenue $1.5M, net loss $16.3M; VA contract awarded","bullets":["Q4 EsoGuard tests 3,664; revenue $1.5M; GAAP net loss $16.3M ($0.12/share); non-GAAP adj. loss $12.6M ($0.10/share).","Cash $34.7M at Dec 31, 2025 vs $22.4M at Dec 31, 2024; operating expenses $15.5M incl $1.2M stock-based comp.","Awarded U.S. Department of Veterans Affairs contract for EsoGuard with $1,938 Medicare-aligned pricing across 170 VA medical centers.","Largest real-world esophageal precancer detection study (nearly 12,000 patients) shows EsoCheck 95% technical success rate and 95% procedures under two minutes."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-012807","json":"https://secwatch.observer/filing/0001493152-26-012807.json","markdown":"https://secwatch.observer/filing/0001493152-26-012807.md","text":"https://secwatch.observer/filing/0001493152-26-012807.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799011/000149315226012807/0001493152-26-012807-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799011/000149315226012807/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:52:09.138095+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"277f0c9d117a139864e864deed4c380676238b65","claim":"Lucid Diagnostics Inc. reported fourth quarter and full year ended December 31, 2025 results: revenue $1.5 million, net income approximately $16.3 million or $(0.12) per common share, EPS $(0.12) per common share.","evidence_excerpt":"--- Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results Processed 3,664 EsoGuard ® tests and recognized 4Q25 revenue of $1.5 million Expanded EsoGuard access with U.S. Department of Veterans Affairs contract award and strengthened clinical evidence with positive data from the largest reported real-world","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1799011/000149315226012807/0001493152-26-012807-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2025"},{"label":"Revenue","value":"$1.5 million"},{"label":"Net income","value":"approximately $16.3 million or $(0.12) per common share"},{"label":"EPS","value":"$(0.12) per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}